Recent Updates
Recently added Catalysts

Diazepam Buccal Soluble Film 5, 7.5, 10, 12.5, 15 or with individual dose determined according to age and weight category

Phase 3

Epilepsy | Small molecule | Neurology |Aquestive Therapeutics, Inc.|Last Updated: Aug 5, 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment149

FDA Designations

No designations recorded

Clinical trial landscape

Diazepam Buccal Soluble Film 5, 7.5, 10, 12.5, 15 or with individual dose determined according to age and weight category · 1 trial · 1 indication

Phase 3 1
NCT03428360Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With EpilepsyEpilepsy
COMPLETED149 Analytics
PHASE3COMPLETED
Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy
EpilepsyUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Subjects in the Safety Analysis Set With at Least 1 Treatment-emergent Adverse Event (TEAE)
Adverse events (AEs) were recorded from Day 1 through the last study contact (Month 7 telephone contact).

A TEAE was defined as any adverse event with onset date on the day of or after administration of study drug including relationship and severity.

Number of Subjects in Safety Analysis Set With Adverse Events of Special Interest (AESI)
AESIs were recorded from Day 1 through the last study contact (Month 7 telephone contact).

A.Oral irritation related AEs including but not limited to: buccal mucosal swelling, mouth ulceration, injuries to oral cavity (such as tongue or mucosal laceration, broken tooth, bleeding), erythema, stomatitis, gingivitis, xerostomia, staining, dysphagia, dysgeusia, burning, stinging, tingling. B. Abuse related AEs including euphoria, euphoric mood, feeling of relaxation, anger, dissociative effects, hallucinations, psychosis, changes in mood, impaired cognition, attention, psychomotor effects, inappropriate affect, overdose, and misuse. C. Other: Respiratory disorders, nervous system disorders

Secondary Endpoints

Usability Assessment: Number of Use Occasions Where Difficulty in Opening the Outer Packaging Was Recorded.
Recorded in an electronic diary after each use of study drug, throughout the course of the study; approximately 6 months
Usability Assessment: Ability to Open Foil Pouch on Each Use Occasion
Recorded in an electronic diary after each use of study drug, throughout the course of the study; approximately 6 months
Usability Assessment: Ability to Remove Study Drug From Foil Pouch on Each Use Occasion
Recorded in an electronic diary after each use of study drug, throughout the course of the study; approximately 6 months
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Subjects with EpilepsyEXPERIMENTALMale or female subjects between the ages of 2 and 65 years who had an established diagnosis of epilepsy exhibited by motor seizures with clear alteration of awareness, and while on a regimen of anti-epileptic medication(s), still experienced bouts of seizures (frequent breakthrough seizures, eg, seizure clusters) and who, in the opinion of the Investigator, could need benzodiazepine intervention for seizure control at least 1 time a month on average. Subjects must have been on at least 1 concomitant anti-epileptic drug at screening.

Interventions

NameTypeDescription
Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight categoryDRUGThe subjects in this study administered DBF themselves or with the help of a caregiver, (trained by the study site staff in study drug administration and documentation) in the same setting as they typically used the diazepam rectal gel or other rescue medication, without the presence of study staff.
Unlock Study Design Details

Eligibility Criteria

Age Range2 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites6

Inclusion Criteria: 1. Female or male subject between the ages of 2 and 65 years of age, inclusive 2. Written informed consent to participate in the study 3. Subject has an established diagnosis of epilepsy either partial or generalized epilepsy with motor seizures with clear alteration of awarenes...

Countries:United States
Unlock Eligibility Criteria